The highest FDA-approved dose of semaglutide is 2.4 mg once weekly, used for weight management under the brand name Wegovy. For type 2 diabetes, the ceiling is lower: 2 mg once weekly with Ozempic. An oral form, Rybelsus, tops out at 14 mg daily. These numbers vary because each formulation was approved for a different condition, and the dose needed to produce meaningful weight loss is higher than what’s required for blood sugar control.
Maximum Doses by Brand and Condition
Semaglutide is sold under three brand names, each with its own dosing ceiling:
- Wegovy (weight management): 2.4 mg injected once weekly. This is the highest approved injectable dose. If you can’t tolerate it, a 1.7 mg maintenance dose is an alternative.
- Ozempic (type 2 diabetes): 2 mg injected once weekly. Maintenance options include 0.5 mg, 1 mg, or 2 mg depending on how well your blood sugar responds.
- Rybelsus (type 2 diabetes, oral): 14 mg taken by mouth once daily. Available in 3 mg, 7 mg, and 14 mg tablets.
The oral and injectable doses aren’t directly comparable. Oral semaglutide has very low absorption in the gut, so a 14 mg tablet delivers far less of the drug into your bloodstream than a 2.4 mg injection.
How You Get to the Highest Dose
No one starts at the maximum. Semaglutide requires a gradual titration over several months to reduce nausea and other gut-related side effects. With Ozempic, the standard schedule begins at 0.25 mg weekly for the first four weeks, then increases to 0.5 mg. From there, your provider may raise the dose in steps up to the 2 mg ceiling based on your blood sugar levels.
Wegovy follows a similar staircase pattern over about 16 to 20 weeks before reaching 2.4 mg. Each step lasts at least four weeks, giving your body time to adjust. Skipping steps or escalating too quickly increases the chance of severe nausea and vomiting, which is the most common reason people discontinue the medication.
What the Highest Doses Achieve
The 2.4 mg Wegovy dose produced an average weight loss of about 15% of body weight over two years in the STEP 5 clinical trial, compared to roughly 2.6% with placebo. In a separate trial (STEP 4), patients who stayed on the full dose lost an average of 17.4% of their body weight over 68 weeks.
For diabetes, the picture is different. Ozempic’s 2 mg dose reduced A1c (a measure of average blood sugar over three months) by 2.1 percentage points at 40 weeks in patients who started with elevated levels around 8.9%. That was modestly better than the 1.9 percentage point reduction seen with the 1 mg dose, a small but statistically significant difference that led to the 2 mg option being added.
A Higher Dose in Development: 7.2 mg
A 7.2 mg weekly injection, triple the current maximum, completed a large phase 3 trial called STEP UP in late 2024. The results, published in The Lancet Diabetes & Endocrinology, showed participants lost an average of 18.7% of their body weight, compared to 15.6% with the standard 2.4 mg dose and 3.9% with placebo.
The higher dose was particularly effective at pushing people past the 20% and 25% weight loss thresholds that the current dose struggles to reach consistently. Participants on 7.2 mg were nearly twice as likely to lose 20% or more of their body weight compared to those on 2.4 mg, and about 2.4 times as likely to lose 25% or more.
The tradeoff was more side effects. About 71% of people on the 7.2 mg dose experienced gastrointestinal problems like nausea, vomiting, or abdominal discomfort, compared to 61% at 2.4 mg and 43% on placebo. A new side effect also appeared more frequently: dysaesthesia, an unusual tingling or numbness sensation, which affected 23% of the high-dose group versus 6% at 2.4 mg. The 7.2 mg dose is not yet FDA-approved, but the trial data suggests it will likely become an option in the near future.
Side Effects at the Highest Approved Doses
Gastrointestinal symptoms are the defining side effect of semaglutide, and they are dose-dependent. Nausea, vomiting, diarrhea, and constipation all become more common as the dose increases. Most of these symptoms are worst during the titration period and improve once your body adjusts to a stable dose. This is the primary reason the gradual dose escalation schedule exists.
For people who can’t tolerate the full 2.4 mg Wegovy dose even after proper titration, stepping back to 1.7 mg is a recognized option that still provides meaningful weight loss, though somewhat less than the top dose.
What Happens if the Maximum Is Exceeded
Dosing errors have been a real concern, particularly with compounded versions of semaglutide that use different concentration formats than the branded products. The FDA has issued alerts specifically about overdose cases linked to compounded injectables. Reported symptoms of overdose include severe nausea, severe vomiting, abdominal pain, fainting, headache, dehydration, and in some cases acute pancreatitis or gallstones.
Because semaglutide has a half-life of about one week, meaning it takes that long for half the drug to leave your system, overdose symptoms can persist for days. There is no antidote; treatment focuses on managing symptoms while the drug clears. This long duration in the body is also why the medication works as a once-weekly injection, but it makes accidental overdoses more consequential than with shorter-acting drugs.